Alembic Pharmaceuticals Limited has informed the Exchange regarding 'Alembic Pharmaceuticals Limited passes ANVISA (Brazil) GMP Inspection for its API-III Facility at Karakhadi'.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP inspection at its API-III Facility located at Karakhadi. The inspection was conducted from 11th to 15th May, 2026 and was completed without any observations, indicating a clean audit. This certification allows the company to export active pharmaceutical ingredients (APIs) to Brazil, a major pharmaceutical market. The company already has other international certifications, and this ANVISA approval further strengthens its global compliance credentials.
Positive for shareholders as the company can now tap into Brazil's large pharmaceutical market for API exports, potentially driving future revenue growth and diversification of its international client base.